GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » EPS (Basic)

INBP (Integrated Biopharma) EPS (Basic) : $0.03 (TTM As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma EPS (Basic)?

Integrated Biopharma's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.03.

Integrated Biopharma's EPS (Diluted) for the three months ended in Dec. 2024 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.03.

Integrated Biopharma's EPS without NRI for the three months ended in Dec. 2024 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was 0.03.

During the past 3 years, the average EPS without NRI Growth Rate was -73.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Integrated Biopharma's highest 3-Year average EPS without NRI Growth Rate was 273.30% per year. The lowest was -138.10% per year. And the median was 19.30% per year.


Integrated Biopharma EPS (Basic) Historical Data

The historical data trend for Integrated Biopharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma EPS (Basic) Chart

Integrated Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.27 0.13 - -

Integrated Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.01 0.01 0.01 -

Integrated Biopharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Integrated Biopharma's Basic EPS for the fiscal year that ended in Jun. 2024 is calculated as

Basic EPS (A: Jun. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.112-0)/30.066
=0.00

Integrated Biopharma's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.116-0)/30.175
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integrated Biopharma  (OTCPK:INBP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Integrated Biopharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from Contract Manufacturing segment which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431